Microvascular disease in diabetes mellitus

Coronary Artery Disease

Volumn 7, Issue 10, 1996, Pages 702-707

  Kollros, Peter R ^a   Konkle, Barbara A ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

diabetes; microangiopathy; nephropathy; retinopathy

Indexed keywords

DIABETES CONTROL; DIABETES MELLITUS; DIABETIC ANGIOPATHY; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; DISEASE ASSOCIATION; FIBRINOLYSIS; HEMODYNAMICS; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MICROANGIOPATHY; MICROVASCULATURE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW;

EID: 0030479037     PISSN: 09546928     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019501-199610000-00002     Document Type: Review

References (86)

1. Klein R, Klein BEK, Moss SE, Davis MD, Demets DL: Glycosylated hemoglobin predicts the incidence and progression of diabetic retinopathy. JAMA 1988, 260:2864-2871.
2. Steffes MW, Sutherland DER, Goetz FC, Rich SS, Mauer SM: Studies of kidney and muscle biopsy specimens from identical twins discordant for type 1 diabetes mellitus. N Engl J Med 1985, 312:1282-1287.
3. Engerman RL, Kern TS: Progression of incipient diabetic retinopathy during good glycemic control. Diabetes 1987, 36:808-812. Documents the progression of diabetic retinopathy in an animal model even after glycemic control is reestablished.
4. Reichard P, Nilsson BY, Rosenqvist U: The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. N Engl J Med 1993, 329:304-309. Documents the benefits of intensive insulin treatment and good glycemic control on the prevention of chronic microangiopathic complications. Also shows in human a time lag of 90 months before the benefit of reduced serious retinopathy becomes apparent in the intensive treatment group.
5. Tooke JE: Microvascular function in human diabetes. Diabetes 1995, 44:721-726. Evidence to support the role of altered hemodynamics in the pathogenesis of microangiopathy.
6. Tooke JE: Microvascular hemodynamics in diabetes mellitus. Clin Sci 1986, 70:119-125.
7. Williams SA, Wassermann S, Rawlinson DW, Kitney RI, Smaje LH, Tooke JE: Dynamic measurement of human capillary blood pressure. Clin Sci 1988, 74:507-512.
8. Sandeman DD, Shore AC, Tooke JE: Relation of skin capillary pressure in patients with insulin-dependent diabetes mellitus to complications and metabolic control. N Engl J Med 1992, 327:760-764.
9. Shore AC, Price KJ, Sandeman DD, Tripp JH, Tooke JE: Posturally induced vasoconstriction in diabetes mellitus. Arch Dis Childhood 1994, 70:22-26.
10. Shore AC, Jaap AJ, Tooke JE: Capillary pressure in insulin dependent diabetic patients of long disease duration with and without microangiopathy. Diabetic Med 1992, 9 (Suppl. 2):S11.
11. Williams SA, Boolell M, MacGregor GA, Smaje LH, Wasserman SM, Tooke JE: Capillary hypertension and abnormal pressure dynamics in patients with essential hypertension. Clin Sci 1990, 79:5-8.
12. Berkman J, Rifkin H: Unilateral nodular diabetic glomerulosclerosis (Kimmel-Steel-Wilson): report of a case. Metabolism 1973, 22:715-722.
13. Duker JS, Brown GC, Bosley TM, Colt CA, Reber R: Asymmetric proliferative diabetic retinopathy and carotid artery disease. Ophthalmology 1990, 97:869-874.
14. Tesfamariam B, Brown ML, Deykin D, Cohen RA: Elevated glucose promotes generation of endothelium-derived vasoconstrictor prostanoids in rabbit aorta. J Clin Invest 1990, 85:929-932.
15. Takahashi K, Ghatei MA, Lam HC, O'Halloran DJ, Bloom SR: Elevated plasma endothelin in patients with diabetes mellitus. Diabetologia 1990, 33:306-310.
16. Molinatti PA, Porta M, Takahashi K, Kanse SM, Brooks RA, Bloom SR, Kohner EM: Endothelin-1 production is reduced in retinal capillary endothelial cells cultured in high glucose [abstract]. Diabetologia 1990, 33:A51.
17. Njoroge FG, Monnier VM: The chemistry of the Maillard reaction under physiological conditions: a review. Prog Clin Biol Res 1989, 304:85-107.
18. Brownlee M, Cerami A, Vlassara H: Advanced glycosylation endproducts in tissue and the biochemical basis of diabetic complications. N Engl J Med 1988, 318:1315-1321.
19. Ledl F, Schleicher E: New aspects of the Maillard reaction in foods and in the human body. 1990, 6:565-706.
20. Perejda AJ, Uitto J: Nonenzymatic glycosylation of collagen and other proteins: relationship to development of diabetic complications. Collagen Relat Res 1982, 2:81-88.
21. Chang K, Ulitto J, Rowold EA, Grant GA, Kilo C, Williamson JR: Increased collagen cross-linkages in experimental diabetes: reversal by B-aminopropionitrile and D-penicillamine. Diabetes 1980, 29:778-781.
22. Monnier VM, Vishwanath V, Frank KE, Elmets CA, Dauchot P, Kohn RR: Relation between complications of type 1 diabetes mellitus and collagen-linked fluorescence. N Engl J Med 1986, 314:403-408.
23. Bucala R, Tracey KJ, Cerami A: Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilation in experimental diabetes. J Clin Invest 1991, 87:432-438.
24. Hogan M, Cerami A, Bucala R: Advanced glycosylation endproducts block the antiproliferative effect of nitric oxide: role in the vascular and renal complications of diabetes mellitus. J Clin Invest 1992, 90:1110-1115.
25. Soulis-Liparota T, Cooper M, Papazoglou D, Clarke B, Jerums G: Retardation by aminoguanidine of development of albuminuria, mesangial expansion, and tissue fluorescence in streptozocin-induced diabetic rat. Diabetes 1991, 40:1328-1334.
26. Kihara M, Schmeltzer JD, Poduslo JF, Curran GL, Nickander KK, Low PA: Aminoguanidine effects on nerve blood flow, vascular permeability, electrophysiology, and oxygen free radicals. Proc Nail Acad Sci USA 1991, 88:6107-6111.
27. Suarez G, Rajarani R, Bhurjan KC, Oronsky L, Goidi JA: Administration of aldose reductase inhibitor induces a decrease of collagen fluorescence in diabetic rats. J Clin Invest 1988, 82:624-627.
28. Nicholls K, Mandel TE: Advanced glycosylation end products in experimental murine diabetic nephropathy: effect of islet grafting and aminoguanidine. Lab Invest 1989, 60:486-491.
29. Osterby R: Basement membrane morphology in diabetes mellitus. In Diabetes Mellitus. Edited by Rifkin H, Port DJ. New York: Elsevier, 1990.
30. Williamson JR, Kilo C: Current status of capillary basement-membrane disease in diabetes mellitus. Diabetes 1977, 26:65-73.
31. Vracko R: Skeletal muscle capillaries in diabetics. Circulation 1970, 41:271-283.
32. Li W, Shen S, Khatami M, Rockey JH: Stimulation of retinal capillary pericyte protein and collagen synthesis in culture by high-glucose concentration. Diabetes 1984, 33:785-789.
33. Cagliero E, Maiello M, Boeri D, Roy S, Lorenzi M: Increased expression of basement membrane components in human endothelial cells cultured in high glucose. J Clin Invest 1988, 82:735-738.
34. Berman A, Ledbetter S: Regulation of type IV collagen mRNA in retinal capillary endothelial cells and pericytes by glucose levels and aldose reductase inhibitor, sorbinil [abstract]. Diabetes 1988, 37 (suppl 1):96A.
35. Bernstein J, Cheng F, Roszka J: Increased glucose increases glomerular basement membrane in metanephric culture. Pediatr Nephiol 1987, 1:3-8.
36. Reddi AS: Collagen metabolism in the retina of normal and diabetic rats. Exp Eye Res 1985, 41:345-352.
37. Panush Cohen M, Khalifa A: Renal glomerular collagen synthesis in streptozotocin diabetes: reversal of increased basement membrane synthesis with insulin therapy. Biochim Biophys Acta 1977, 500:395-404.
38. Sprio RG, Spiro MJ: Effect of diabetes on the biosynthesis of the renal glomerular basement membrane: studies on the glucosyltransferase. Diabetes 1971, 20:641-648.
39. Steffes MW, Osterby R, Chavers B, Mauer SM: Mesangial expansion as a central mechanism for loss of kidney function in diabetic patients. Diabetes 1989, 38:1077-1081.
40. Riser BL, Cortes P, Zhao X, Bernstein J, Dumler F, Narins RG, et al.: Intraglomerular pressure and mesangial stretching stimulate extracellular matrix formation in the rat. J Clin Invest 1993, 91:1932-1943.
41. Cogan DG, Toussaint D, Kuwabara T: Retinal vascular patterns. IV. Diabetic retinopathy. Arch Ophthalmol 1961, 66:366-378.
42. Ashton N: Studies of the retinal capillaries in relation to diabetic and other retinopathies. Br J Ophthalmol 1963, 47:521-538.
43. Tilton RG, Faller AN, Burkhardt JK, Hoffmann PL, Kilo C, Williamson JR: Pericyte degeneration and acellular capillaries are increased in the feet of human diabetic patients. Diabetologia 1985, 28:898-900.
44. Vracko R: A comparison of the microvascular lesions in diabetes mellitus with those in normal aging. J Am Geriatr Soc 1982, 30:201-205.
45. Fenton BM, Zweifach BW, Worthen DM: Quantitative morphometry of conjunctival microcirculation in diabetes mellitus. Microvasc Res 1979, 18:153-166.
46. Jakobsen J, Sidenius P, Gundersen HJG, Osterby R: Quantitative changes of cerebral neocortical structure in insulin-treated long-term streptozocin-induced diabetes in rats. Diabetes 1987, 36:597-601.
47. Lorenzi M, Cagliero E: Pathobiology of endothelial and other vascular cells in diabetes mellitus. Diabetes 1991, 40:653-659. Documents changes in microvascular cells with diabetes and critiques areas which need further investigation.
48. Speiser P, Gittelsohn AM, Patz A: Studies on diabetic retinopathy. III. Influence of diabetes on intramural pericytes. Arch Ophthalmol 1968, 80:332-337.
49. Bito AL, DeRousseau CJ: Transport function of the blood-retinal barrier system and the micro-environment of the retina. In The Blood Retinal Barriers. Edited by Chauna-Vaz JD. New York: Plenum Press, 1980.
50. Bloodworth JMB: A re-evaluation of diabetic glomerulo-sclerosis 50 years after the discovery of insulin. Human Pathol 1978, 9:439-453.
51. Factor SM, Okun EM, Minase T: Capillary microaneurysms in the human diabetic heart. N Engl J Med 1980, 302:384-388.
52. Wise GN: Retinal microaneurysms. AMA Arch Ophthalmol 1957, 57:151-156.
53. Kador PF, Akagi Y, Takahashi Y, Ikebe H, Wyman M, Kinoshita JH: Prevention of retinal vessel changes associated with diabetic retinopathy in galactose-fed dogs by aldose reductase inhibitors. Arch Ophthalmol 1990, 108:1301-1309.
54. Sato Y, Rifkin DB: Inhibition of endothelial cell movement by pericytes and smooth muscle cells: activation of a latent transformation growth factor B1-like molecule by plasmin during co-culture. J Cell Biol 1989, 109:309-315.
55. Antonelli-Orlidge A, Saunders KB, Smith SR, D'Amore PA: An activated form of transforming growth factor B is produced by cocultures of endothelial cells and pericytes. Proc Natl Acad Sci USA 1989, 86:4544-4548.
56. Deckert T, Feldt-Rasmussen B, Borch-Johnsen K, Jensen T, Kofoed Enevoldsen A: Albuminuria reflects widespread vascular damage: the Steno hypothesis. Diabetologica 1989, 32:219-226.
57. Williamson JR, Chang K, Frangos M, Hasan KS, Ido Y, Kawamura T, et al.: Perspectives in diabetes: hyperglycemic pseudohypoxia and diabetic complications. Diabetes 1993, 42:801-813.
58. United Kingdom Prospective Diabetes Study: United Kingdom Prospective Diabetes Study III: prevalence of hypertension and hypotensive therapy in patients with newly diagnosed diabetes. Hypertension 1985, 7 (suppl 2):8-13.
59. Sandeman DD, Pym CA, Green EM, Seamark C, Shore AC, Tooke JE: Microvascular vasodilatation in feet of newly diagnosed non-insulin dependent diabetic patients. BMJ 1991, 302:1122-1123.
60. Jaap AJ, Hammersley MS, Shore AC, Tooke JE: Reduced microvascular hyperaemia in subjects at risk of developing type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1994, 37:214-216.
61. Welborn TA, Breckenridge A, Rubinstein AH, Dollery CT, Fraser TR: Serum insulin in essential hypertension and in peripheral vascular disease. Lancet 1966, i:1336-1337.
62. Donahue RP, Skyler JS, Schneiderian N, Prineas RJ: Hyperinsulinemia and elevated blood pressure: cause, confounder, or coincidence? Am J Epidemiol 1990, 132:827-836.
63. Kaplan NM: The deadly quartet: upper-body adiposity, glucose intolerance, hypertriglyceridemia and hypertension. Arch Intern Med 1989, 149:1514-1520.
64. Haffner SM, Valdez RA, Hazuda HP, Mitchell BD, Morales PA: Prospective analysis of the insulin resistance syndrome (syndrome X). Diabetes 1992, 41:715-722.
65. Stern MP, Morales PA, Haffner SM, Valdez RA: Hyperdynamic circulation and the insulin resistance syndrome ('syndrome X'). Hypertension 1992, 20:802-808.
66. Jiang X, Srinivasan SR, Urbina E, Berenson GS: Hyperdynamic circulation and cardiovascular risk in children and adolescents. The Bogalusa Heart Study. Circulation 1995, 91:1101-1106.
67. Juhan-Vague I, Alessi MC, Vague P: Increased plasma plasminogen activator inhibitor 1 levels: a possible link between insulin resistance and artherothrombosis. Diabetologia 1991, 34:457-462.
68. Schneider DJ, Nordt TK, Sobel BE: Attenuated fibrinolysis and accelerated atherosclerosis in type II diabetic patients. Diabetes 1993, 42:1-7.
69. Kooistra T, Bosma PJ, Tons HAM, van den Berg AP, Meyer P, Princen HMG: Plasminogen activator inhibitor 1: biosynthesis and mRNA level are increased by insulin in cultured human hepatocytes. Thromb Haemos 1989, 62:723-728.
70. Nordt TK, Sawa H, Fujii S, Sobel BE: Induction of plasminogen activator inhibitor type-1 (PAI-1) by proinsulin and insulin in vivo. Circulation 1995, 91:764-770.
71. Kollros PR, Konkle BA, Ambarian AP, Henrikson P: Plasminogen activator inhibitor-1 expression by brain microvessel endothelial cells is inhibited by elevated glucose. J Neurochem 1994, 63:903-909.
72. Werb Z, Banda MJ, Jones PA: Degradation of connective tissue matrices by macrophages. I. Proteolysis of elastin, glycoproteins and collagen by proteinases isolated from macrophages. J Exp Med 1980, 152:1340-1357.
73. Werb Z, Mainardi C, Vater CA, Harris JED: Endogenous activation of latent collagenase by rheumatoid synovial cells. Evidence for a role of plasminogen activator. N Engl J Med 1977, 296:1017-1023.
74. Ingber DE, Folkman J: How does extracellular matrix control capillary morphogenesis? Cell 1989, 58:803-805. This reference presents an interesting perspective on matrix cell interactions.
75. Hsueh WA, Anderson PW: Systemic hypertension and the renin-angiotensin system in diabetic vascular complications. Am J Cardiol 1993, 72:14H-21H.
76. Karpen CW, Spanheimer RG, Randolph AL, Lowe JWL: Tissue-specific regulation of basic fibroblase growth factor mRNA levels by diabetes. Diabetes 1992, 41:222-226.
77. Ruderman NB, Williamson JR, Brownlee M: Glucose and diabetic vascular disease. FASEB J 1992, 6:2905-2914. This review examines how diabetes causes disruptions in cell physiology. It describes a number of pathophysiologic sequences and how they may relate to one another.
78. Bank N, Mower P, Aynedijian HS, Wilkes BM, Silverman S: Sorbinil prevents glomerular hyperperfusion in diabetic rats. Am J Physiol 1989, 256:F1000-F1006.
79. Greene DA, Lattimer SA, Sima AAF: Pathogenesis and prevention of diabetic neuropathy. Diab/Metab Rev 1988, 5:202-221.
80. Winegrad AI: Does a common mechanism induce the diverse complications of diabetes? Diabetes 1987, 36:396-406.
81. Craven PA, Davidson CM, DeRubertis FR: Increase in diacylglycerol mass in isolated glomeruli by glucose from de novo synthesis of glycerolipids. Diabetes 1990, 39:667-674.
82. Lee TS, MacGregor LC, Fluharty SJ, King GL: Differential regulation of protein kinase C and (Na,K)-adenosine triphosphatase activities by elevated glucose levels in retinal capillary endothelial cells. J Clin Invest 1989, 83:90-94.
83. Lee TS, Saltsman KA, Ohashi H, King GL: Activation of protein kinase C by elevated glucose concentration: proposal for a mechanism in the development of diabetic vascular complications. Proc Natl Acad Sci USA 1989, 86:5141-5145.
84. Craven PA, DePubertis FR: Sorbinil suppresses glomerular prostaglandin production in the streptozotocin diabetic rat Metabolism 1989, 38:649-654.
85. Simmons DA, Winegrad AI: Mechanism of glucose-induced (Na,K)-ATPase inhibition in aortic wall of rabbits. Diabetologia 1990, 32:402-408.
86. Pugliese G, Tilton RG, Speedy A, Santarelli E, Eades DM, Province MA, et al.: Modulation of hemodynamic and vascular filtration changes in diabetic rats by dietary myo-inositol. Diabetes 1990, 39:312-322.